Title:
HUMANIZED ANTI-CD19 ANTIBODY FORMULATIONS
Document Type and Number:
WIPO Patent Application WO/2010/102276
Kind Code:
A3
Abstract:
The present invention provides stable liquid formulations comprising chimeric and humanized versions of anti-CD 19 mouse monoclonal antibodies that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders.
Inventors:
SHARMA MONIKA (US)
SHAH AMBARISH (US)
SHAH AMBARISH (US)
Application Number:
PCT/US2010/026492
Publication Date:
November 11, 2010
Filing Date:
March 08, 2010
Export Citation:
Assignee:
MEDIMMUNE LLC (US)
SHARMA MONIKA (US)
SHAH AMBARISH (US)
SHARMA MONIKA (US)
SHAH AMBARISH (US)
International Classes:
A61K39/395
Domestic Patent References:
| WO2008031056A2 | 2008-03-13 |
Foreign References:
| US7109304B2 | 2006-09-19 |
Other References:
ZALEVSKY ET AL.: "The impact of Fc engineering on an anti-CD19 antibody: increased Fc gamma receptor affinity enhances B-cell clearing in nonhuman primates.", BLOOD, vol. 13, no. 16, 16 April 2009 (2009-04-16), pages 3735 - 3743, XP002685051
See also references of EP 2403532A4
See also references of EP 2403532A4
Attorney, Agent or Firm:
HOLMES-SON, Michelle et al. (LLCOne Medimmune Wa, Gaithersburg MD, US)
Download PDF: